Peptide Fragments

Antiviral Agents
Baseline Genotypic and Phenotypic Susceptibilities of HIV-1 Group O to Enfuvirtide
Agnès Depatureaux, Charlotte Charpentier, Gilles Collin, Marie Leoz, Diane Descamps, Aurélia Vessière, Florence Damond, Dominique Rousset, Françoise Brun-Vézinet, Jean-Christophe Plantier
Susceptibility
Peptide Fragments of a β-Defensin Derivative with Potent Bactericidal Activity
Natalie L. Reynolds, Martin De Cecco, Karen Taylor, Chloe Stanton, Fiona Kilanowski, Jason Kalapothakis, Emily Seo, Dusan Uhrin, Dominic Campopiano, John Govan, Derek Macmillan, Perdita Barran, Julia R. Dorin
Biologic Response Modifiers
Antimicrobial Peptide hLF1-11 Directs Granulocyte-Macrophage Colony-Stimulating Factor-Driven Monocyte Differentiation toward Macrophages with Enhanced Recognition and Clearance of Pathogens
Anne M. van der Does, Sylvia J. P. Bogaards, Bep Ravensbergen, Henry Beekhuizen, Jaap T. van Dissel, Peter H. Nibbering
Antiviral Agents
Long-Lasting Enfuvirtide Carrier Pentasaccharide Conjugates with Potent Anti-Human Immunodeficiency Virus Type 1 Activity
Thierry Huet, Olivier Kerbarh, Dominique Schols, Pascal Clayette, Cécile Gauchet, Guy Dubreucq, Loïc Vincent, Heidi Bompais, Romain Mazinghien, Olivier Querolle, Arnaud Salvador, Jérôme Lemoine, Bruno Lucidi, Jan Balzarini, Maurice Petitou
Antiviral Agents
LFA-1 Antagonists as Agents Limiting Human Immunodeficiency Virus Type 1 Infection and Transmission and Potentiating the Effect of the Fusion Inhibitor T-20
Mélanie R. Tardif, Caroline Gilbert, Sandra Thibault, Jean-François Fortin, Michel J. Tremblay
Antiviral Agents
Treatment with the Fusion Inhibitor Enfuvirtide Influences the Appearance of Mutations in the Human Immunodeficiency Virus Type 1 Regulatory Protein Rev
Valentina Svicher, Claudia Alteri, Roberta D'Arrigo, Alessandro Laganà, Maria Trignetti, Sergio Lo Caputo, Anna Paola Callegaro, Franco Maggiolo, Francesco Mazzotta, Alfredo Ferro, Salvatore Dimonte, Stefano Aquaro, Giovanni di Perri, Stefano Bonora, Chiara Tommasi, Maria Paola Trotta, Pasquale Narciso, Andrea Antinori, Carlo Federico Perno, Francesca Ceccherini-Silberstein
Antiviral Agents
Safety and Efficacy of Enfuvirtide in Combination with Darunavir-Ritonavir and an Optimized Background Regimen in Treatment-Experienced Human Immunodeficiency Virus-Infected Patients: the Below the Level of Quantification Study
Edwin DeJesus, Michael S. Gottlieb, Joseph C. Gathe, Michael L. Greenberg, Carol Jean Guittari, Andrew R. Zolopa
Antiviral Agents
Rapamycin Reduces CCR5 Density Levels on CD4 T Cells, and This Effect Results in Potentiation of Enfuvirtide (T-20) against R5 Strains of Human Immunodeficiency Virus Type 1 In Vitro
Alonso Heredia, Bruce Gilliam, Olga Latinovic, Nhut Le, Douty Bamba, Anthony DeVico, Gregory B. Melikyan, Robert C. Gallo, Robert R. Redfield
Mechanisms of Action: Physiological Effects
Immunomodulatory Peptide from Cystatin, a Natural Cysteine Protease Inhibitor, against Leishmaniasis as a Model Macrophage Disease
Snigdha Mukherjee, Anindita Ukil, Pijush K. Das
Mechanisms of Action: Physiological Effects
Inhibition of Anthrax Protective Antigen Outside and Inside the Cell
Marina V. Backer, Vimal Patel, Brian T. Jehning, Kevin P. Claffey, Vladimir A. Karginov, Joseph M. Backer

Main menu

User menu

Search

Peptide Fragments

Pages